ACT 178882

Drug Profile

ACT 178882

Alternative Names: ACT-178882; MK-1597

Latest Information Update: 01 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Actelion Pharmaceuticals; Merck & Co
  • Developer Actelion Pharmaceuticals
  • Class Amides; Antihypertensives; Piperidines; Pyrimidines
  • Mechanism of Action Renin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Hypertension

Most Recent Events

  • 05 Feb 2013 Phase-I clinical trials in Hypertension in Switzerland (PO)
  • 05 Feb 2013 Drug interactions & adverse events data from a phase I trial in Healthy volunteers released by Actelion Pharmaceuticals
  • 19 Jul 2012 ACT 178882 is available for licensing as of 19 Jul 2012.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top